The Role of GABA Transaminase ABAT in Pediatric Brain Tumor Medulloblastoma Development and Spread
The Role of GABA Transaminase ABAT in Pediatric Brain Tumor Medulloblastoma Development and Spread
批准号:
10716956
负责人:
ANAT ERDREICH-EPSTEIN
金额:
$57.96万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-06-01 至 2028-02-28
关键词:
4-Aminobutyrate aminotransferaseATAC-seqAmino Acid SequenceBARHL1 geneBiologicalBiological AssayBlood - brain barrier anatomyBrainCell NucleusCellsCerebellumCerebrospinal FluidCessation of lifeCharacteristicsChildChildhood Brain NeoplasmChildhood Malignant Brain TumorChromatin StructureCisplatinCompetenceControl AnimalCytoplasmic GranulesDataDevelopmentDiseaseEnergy-Generating ResourcesEnzymesEpigenetic ProcessFoundationsGene ActivationGenetic TranscriptionGoalsGrowthHistone AcetylationHistone DeacetylaseHistone H3HumanImmunoprecipitationIn VitroLeptomeningesLesionLifeLysineMalignant NeoplasmsMaximum Tolerated DoseMetabolicMetabolismMetastatic Neoplasm to the LeptomeningesMitochondriaModificationMusNeoplasm MetastasisNervous SystemNeurobiologyNeurogliaNeuronsNeurosciencesNeurotransmittersNuclearNutrientOncogenesOutcomePaperPathogenesisPatientsPharmaceutical PreparationsPhenotypePrimary NeoplasmProliferatingPublishingReceptor ActivationReportingResearchRoleRouteShunt DeviceSignal TransductionSiteSpectrum AnalysisTherapeuticToxic effectTransgenic MiceVincristineXenograft procedureblood-brain barrier crossingblood-brain barrier permeabilizationcomparison controlgamma-Aminobutyric Acidin vivoinduced pluripotent stem cellinducible gene expressioninhibitorknock-downmedulloblastomamortalitymouse modelneoplastic cellnerve stem cellneuralneurodevelopmentnovelnovel therapeutic interventionoverexpressionprotein H(3)radiation resistancereceptorsmall moleculestandard of carestem cell differentiationtherapeutic targettranscriptometranscriptome sequencingtumortumor microenvironmenttumorigenic
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Medulloblastoma (MB), is the most common pediatric brain tumor originating in the GABA-rich cerebellum. 40% of MB
patients present as both cerebellar and cerebral spinal fluid (CSF) leptomeningeal metastases which results in having dismal
outcomes. The project’s long-term goal is to determine how MB become life-threatening leptomeningeal metastases by
studying the tumor and brain microenvironment from a neurodevelopment and cancer neuroscience perspective. Although
abnormal GABAergic receptor activation has been described in group 3 MB, no studies until ours recently had yet
to elucidate the contribution of receptor-independent GABA metabolism to MB pathogenesis and metastasis. Overall,
we were the first to identify GABA metabolic shunt enzyme GABA Transaminase (ABAT) expression is correlated with
cerebellar development and is used by MB to survive in the cerebrospinal fluid microenvironment and promote
leptomeningeal dissemination. Specifically, we show proliferative MB cells at the primary cerebellar site have low ABAT.
However, a sub-population of ABAT positive MB cells at the primary cerebellar site display neuron-like characteristics
(including metabolism) and are the seeds of MB metastasis. In addition to being a GABA metabolic enzyme, we determined
that expression of ABAT induces epigenetic modification by significantly reducing histone acetylation at the 4th lysine
residue of the histone H3 protein (H3K4ac) and significantly increase in histone deacetylase activity. Furthermore, ABAT
expression fluctuates depending on metabolite changes in the tumor microenvironment, with nutrient-poor conditions
upregulating ABAT expression. We found metastatic MB cells require ABAT to maintain viability in the metabolite-scarce
CSF by using GABA through the GABA metabolic shunt as an energy source substitute, thereby facilitating leptomeningeal
metastasis formation. Therefore, we hypothesize ABAT has a dual-biological role: lack of its expression during normal
cerebellar development contributes to proliferation leading to group 3 medulloblastoma formation; While its
overexpression after MB development results in tumor dormancy leading to survival benefit in disseminated cells in
leptomeningeal metastasis. Utilizing foundations of neurobiology by using: a) human and mouse-derived neural stem cells,
neurons and glial cells, b) unique strengths of patient-xenografts, c) BarTeL transgenic mice, d) novel small molecule ABAT
inhibitor which crosses the blood-brain barrier, we will: 1st interrogate the role of ABAT in cerebellar neurodevelopment
and Group 3 MB initiation, 2nd contribution of nuclear ABAT to transcription through histone acetylation modification in
metastases, 3rd investigate ABAT as a potential therapeutic target for MB metastases. The current proposal will shed further
light on understanding how metastatic MB cells develop and adapt to their neural niche opening avenues for novel
therapeutic interventions for children that have this devastating disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Summer Oncology Research Fellowship for Medical Students
-
批准号:10260412
-
项目类别:
-
资助金额:$28.08万
-
财政年份:2019
-
负责人:ANAT ERDREICH-EPSTEIN
-
依托单位:
Summer Oncology Research Fellowship for Medical Students
-
批准号:10453624
-
项目类别:
-
资助金额:$23.46万
-
财政年份:2019
-
负责人:ANAT ERDREICH-EPSTEIN
-
依托单位:
Summer Oncology Research Fellowship for Medical Students
-
批准号:10672333
-
项目类别:
-
资助金额:$28.39万
-
财政年份:2019
-
负责人:ANAT ERDREICH-EPSTEIN
-
依托单位:
Stabilizing PID1 to improve medulloblastoma response to cisplatin
-
批准号:9651649
-
项目类别:
-
资助金额:$25.43万
-
财政年份:2018
-
负责人:ANAT ERDREICH-EPSTEIN
-
依托单位:
Molecular mechanism of PID1, a novel tumor inhibitor, in glioblastomas
-
批准号:9020123
-
项目类别:
-
资助金额:$21.85万
-
财政年份:2015
-
负责人:ANAT ERDREICH-EPSTEIN
-
依托单位:
Therapy for leptomeningeal medulloblastoma by a novel implantable pump
-
批准号:8840675
-
项目类别:
-
资助金额:$22.93万
-
财政年份:2014
-
负责人:ANAT ERDREICH-EPSTEIN
-
依托单位:
Tumor-Inhibitory Effects of P1D1 in Gliomas
-
批准号:8329626
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2011
-
负责人:ANAT ERDREICH-EPSTEIN
-
依托单位:
Tumor-Inhibitory Effects of P1D1 in Gliomas
-
批准号:8227304
-
项目类别:
-
资助金额:$24.0万
-
财政年份:2011
-
负责人:ANAT ERDREICH-EPSTEIN
-
依托单位:
Ceramide in angiogenic integrin signaling
-
批准号:6861211
-
项目类别:
-
资助金额:$9.82万
-
财政年份:2005
-
负责人:ANAT ERDREICH-EPSTEIN
-
依托单位:
Ceramide in angiogenic integrin signaling
-
批准号:7060518
-
项目类别:
-
资助金额:$9.59万
-
财政年份:2005
-
负责人:ANAT ERDREICH-EPSTEIN
-
依托单位:
Brain tumor angiogenesis: Integrin ceramide signaling
-
批准号:6825097
-
项目类别:
-
资助金额:$30.32万
-
财政年份:2004
-
负责人:ANAT ERDREICH-EPSTEIN
-
依托单位:
Brain tumor angiogenesis: Integrin ceramide signaling
-
批准号:7227715
-
项目类别:
-
资助金额:$26.64万
-
财政年份:2004
-
负责人:ANAT ERDREICH-EPSTEIN
-
依托单位:
Brain tumor angiogenesis: Integrin ceramide signaling
-
批准号:7104361
-
项目类别:
-
资助金额:$27.44万
-
财政年份:2004
-
负责人:ANAT ERDREICH-EPSTEIN
-
依托单位:
Brain tumor angiogenesis: Integrin ceramide signaling
-
批准号:6922911
-
项目类别:
-
资助金额:$28.1万
-
财政年份:2004
-
负责人:ANAT ERDREICH-EPSTEIN
-
依托单位:
Brain tumor angiogenesis: Integrin ceramide signaling
-
批准号:7429686
-
项目类别:
-
资助金额:$26.64万
-
财政年份:2004
-
负责人:ANAT ERDREICH-EPSTEIN
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于ATAC-seq与DNA甲基化测序探究染色质可及性对莲两生态型地下茎适应性分化的作用机制
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:
-
依托单位:
利用ATAC-seq联合RNA-seq分析TOP2A介导的HCC肿瘤细胞迁移侵
袭的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:柳静
-
依托单位:
面向图神经网络ATAC-seq模体识别的最小间隔单细胞聚类研究
-
批准号:62302218
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:张双全
-
依托单位:
基于ATAC-seq策略挖掘穿心莲基因组中调控穿心莲内酯合成的增强子
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:黄铭坤
-
依托单位:
基于单细胞ATAC-seq技术的C4光合调控分子机制研究
-
批准号:32100438
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:涂晓雨
-
依托单位:
基于ATAC-seq技术研究交叉反应物质197调控TFEB介导的自噬抑制子宫内膜异位症侵袭的分子机制
-
批准号:82001520
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:汤小晗
-
依托单位:
靶向治疗动态调控肺癌细胞DNA可接近性的ATAC-seq分析
-
批准号:81802809
-
项目类别:青年科学基金项目
-
资助金额:21.0万元
-
批准年份:2018
-
负责人:蔡梅春
-
依托单位:
运用ATAC-seq技术分析染色质可接近性对犏牛初级精母细胞基因表达的调控作用
-
批准号:31802046
-
项目类别:青年科学基金项目
-
资助金额:27.0万元
-
批准年份:2018
-
负责人:张龚炜
-
依托单位:
基于ATAC-seq和RNA-seq研究CWIN调控采后番茄果实耐冷性作用机制
-
批准号:31801915
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2018
-
负责人:茹磊
-
依托单位:
基于ATAC-seq高精度预测染色质相互作用的新方法和基于增强现实的3D基因组数据可视化
-
批准号:31871331
-
项目类别:面上项目
-
资助金额:59.0万元
-
批准年份:2018
-
负责人:张治华
-
依托单位: